Press Releases

January 24, 2017

For more information, contact
Glenn E. Martin at (520) 818-8582

WEED, Inc. to Return to Full SEC Reporting Status

World-Class Cannabis Research Organization Set to Become Leader in the Global Cannabis Industry

TUCSON, AZ / ACCESSWIRE / January 24, 2017 / WEED, Inc. (BUDZ: OTC Pink) (the “Company” or “WEED”), fka United Mines, Inc., a current non-SEC reporting company, announces its goals for 2017. WEED intends to become a vertically integrated holding company in the “seed to sale” cannabis business through mergers, acquisitions, and joint venture collaborations. WEED will contract its own team of world respected specialized Medical Doctors, geneticists, scientists, engineers, technicians and farming consultants. This unison collaborates decades of expertise and innovative working knowledge in the fields of genetics and phytochemistry, together with botany and ecology, sustainability and bacteriology environmentalists, agronomy and permaculture specialists, in addition to utilizing the worlds latest technological advances in growing equipment and facilities, seed pollination, propagation and cultivation; cloning and cross breeding, genetic testing and germplasm storage, cloning and germplasm genetic storage. WEED’s plans commence with extensive background research into the biomedical and phytochemical applications and Cannabis related treatments focused on the human endo-cannabinoid system, more specifically, targeted research into genomics, metabolomics, phytochemicals and secondary metabolites in both Australia and the USA, will result in the production of the required scientifically valid, evidence based, cannabis strains and identification and production of disease specific medicines.

WEED’s conduction of DNA sequencing with genomic and phytochemical studies will further expand the proficiency of WEED Inc.’s cannabis botany and medicinal applications. After the identification; collection and storage of disease specific strains, WEED looks to develop and maintain “WEED” exclusive cannabis seed banks and proprietary strains, targeting a variety of different medical conditions and disorders via consulting agreements with Australian scientist and lead researcher, Ms. Karen Harland and United States based Sangre AgroTech Labs, a genomic research and breeding company in the United States comprised of top-echelon scientists with extensive expertise in plant biology, molecular biology, and genomic sequencing, utilizing the most advanced sequencing technologies and proprietary bioinformatics data systems available.

Ms. Karen Harland commented, “It is an exceptional honor and privilege to research with and amongst some of the world’s most prestigious and knowledgeable experts in plant sciences, human health, disease and medicine. I have no doubt, that our research will add expressively to the worlds scientific and medical literature. Notwithstanding that, WEEDs unrelenting quest for solutions, together with our highly specialized scientific research facilities, WEED will collect the data we ultimately need to sequence in order to start producing the world’s highest quality medical cannabis products”.

The Company intends to return to full reporting status with the Securities and Exchange Commission, and to raise funds to support its activities. To date, no binding agreements have been executed with respect to any of the foregoing, other than the agreements with Ms. Harland and Sangre AgroTech. WEED Inc. of the USA will establish WEED LTD, an unlisted public company and wholly owned subsidiary, in Australia where legal medicinal cannabis cultivation became law on October 30, 2016, to begin strain-specific and disease-specific clinical trials.

“After 47 years of advocacy in this industry, it has been and will continue to be an honor to build the ‘American Dream’ on this new legal frontier with my co-founders, Nicole Marie Breen, my daughter and her husband, Ryan Breen,” said WEED co-founder and CEO Glenn E. Martin. “The CURES are out there. I am optimistic about WEED’s corporate strategy to become a world leader in cannabis research discoveries.”

About WEED, Inc.

WEED, Inc. (BUDZ: OTC Pink) is a USA based public company. WEED Inc is a multi-national, multi-faceted, vertically integrated World Class Cannabis organization. WEED is structured as a holding company doing business through its divisions, wholly owned subsidiaries and strategically placed collaborative partners to achieve & promote our Global Brand. WEED is dedicated to its Global goals and outreach across the full spectrum of the Cannabis industry to find treatments and medical cures utilizing the Cannabaceae plant.

WEED does not grow, harvest, produce or sell any substance in violation of US Federal law under The Federal Controlled Substances Act and meets all standards of International law in the countries that WEED does business in. WEED will purchase land and build commercial grade “cultivation & research centers” to consult, assist, manage & lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical cannabis sector. The Company’s plan is to become a true “Seed-to-Sale” global brand providing infrastructure, financial solutions, medical research and education, along with real estate solutions in this new emerging market. For additional information about WEED, Inc., please visit

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business, including that we have a limited operating history and very limited funds, are dependent upon key personnel whose loss may adversely impact our business, some of our potential business activities, while believed to be compliant with applicable state law, may be illegal under federal law because they violate the Federal Controlled Substances Act, and we may be subject to the risks related to the cost, delays and uncertainties associated with potential future scientific research, product development, clinical trials and the regulatory approval process. We may not be able to enter into binding agreements related to the subject matter of this press release on terms favorable to us or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.


For more information, contact
Glenn E. Martin at (520) 818-8582

Stay Informed

Sign up to receive our latest news and announcements